Storyline
AstraZeneca’s tozorakimab shows strong phase 3 results in COPD trials
AstraZeneca’s lung drug tozorakimab, targeting IL-33, achieved positive outcomes in two phase 3 trials for chronic obstructive pulmonary disease (COPD).
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- BioPharma Divebiopharmadive.com
- Where others missed, AZ's IL-33 drug hits the mark in COPDpharmaphorum
- AstraZeneca’s chronic obstructive pulmonary disease drug candidate has hit the mark in a pair of phase 3 trials, deli...Fierce Biotech